Coeptis Therapeutics, Inc. (COEP)

Coeptis Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	1.47	3.79	2.18	0.2	0
Short-Term Investments	3.5	0	0	0	0
Cash & Cash Equivalents	4.97	3.79	2.18	0.2	0
Cash Growth	31.07%	73.95%	973.86%	40091.09%	-
Receivables	0	0.01	0	0.02	0
Other Current Assets	0.28	0.14	0	0	0
Total Current Assets	5.25	3.94	2.18	0.22	0
Property, Plant & Equipment	0.11	0.07	0.03	0.07	0
Other Long-Term Assets	2.71	3.9	4.55	0	0.17
Total Long-Term Assets	2.82	3.97	4.59	0.08	0.17
Total Assets	8.07	7.92	6.77	0.3	0.17
Accounts Payable	1.42	0.1	0.13	1.62	0
Deferred Revenue	0	0	0	1	0
Current Debt	1.01	1.89	2.43	1.92	0.15
Other Current Liabilities	0.56	0.18	0.2	0.73	0
Total Current Liabilities	2.99	2.17	2.76	5.28	0.16
Long-Term Debt	0.21	0.16	1.65	0.16	0
Other Long-Term Liabilities	0.56	1.13	0	0	0
Total Long-Term Liabilities	0.77	1.29	1.65	0.16	0
Total Liabilities	3.76	3.46	4.41	5.44	0.16
Total Debt	1.22	2.06	4.08	2.09	0.15
Debt Growth	-40.47%	-49.62%	95.50%	1267.78%	-
Retained Earnings	-87.36	-66.09	-27.55	-14.1	-0.01
Shareholders' Equity	4.31	4.45	2.35	-5.14	0.02
Net Cash / Debt	3.74	1.73	-1.9	-1.88	-0.15
Net Cash / Debt Growth	115.85%	-	-	-	-
Net Cash Per Share	0.15	0.12	-0.17	-0.10	-0.09
Working Capital	2.26	1.77	-0.59	-5.05	-0.16
Book Value Per Share	0.17	0.31	0.21	-0.28	0.01

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).